Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 1 of 74
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 2 of 74
Administrative Record Index
Description Date Bates NumberLetter from Charles Ryan, Director, Arizona Department of Corrections, to David Thomas, FDA Investigations re: Execution by Lethal Injection of Arizona Inmate Jeffrey Timothy Landrigan #082157 9/24/2010 000001Letter from Charles Flanagan, Deputy Director, Arizona Department of Corrections, to David Thomas, FDA Investigations, enclosing Controlled Substance Registration Certificate 9/24/2010 000002-000003Notice of FDA Action 9/29/2010 000004Department of Treasury, U.S. Customs Service Entry/Immediate Delivery Form 10/7/2010 000005-00006FDA's Operational and Administrative System for Import Support (OASIS) Screenshot for Entry # 112-9247186-3 n/a 000007Letter from Dale Baich, Supervisor, Capital Habeas Unit, Office of the Federal Public Defender for the District of Arizona, to Ralph Tyler, Chief Counsel, FDA 10/23/2010 000008-000012Department of Homeland Security, U.S. Customs and Border Protection Entry/Immediate Delivery Form 10/25/2010 000013-000015FDA's OASIS Screenshot for Entry # 574-0251126-5 n/a 000016Email from Patrick Bowen, FDA, to Distribution re: Import Bulletin #60-B08 10/27/2010 000017-000018Email from Nima Abbaszadeh, U.K. Desk Officer, U.S. Department of State, to Ilisa Bernstein re: assistance on sodium thiopental question raised by UK Embassy, enclosing Letter from Ian Bond, Political Counsellor, British Embassy Washington, to Elizabeth Dibble, Deputy Assistant Secretary of State 11/4/2011 000019-000020Email from Clare Bloomfield, British Embassy, to Murray Lumpkin, FDA, re: UK request for information on sodium thiopental 11/4/2010 000021Email from Tom Smith, Department for Business, Innovation and Skills, to Murray Lumpkin re: Sodium Thiopental 11/5/2010 000022Email from Murray Lumpkin to Tom Smith cc JM Sharfstein and Margaret Hamburg re: Substantive response from US FDA re: Sodium Thiopental 11/16/2010 000023-000024Letter from Charles Ryan, Director, Arizona Department of Corrections, to Deborah Autor, Director, Office of Compliance, CDER, re: Entry #574-0251126-5 Thiopental Sodium 11/10/2010 000025-000026
1 of 2
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 3 of 74
Administrative Record Index
Letter from Charles Ryan, Director, Arizona Department of Corrections, to David Thomas, FDA Investigations, re: Inspection and Release of Entry #574-0251126-5, Thiopental Sodium 11/10/2010 000027Letter from Dale Baich, Supervisor, Capital Habeas Unit, Office of the Federal Public Defender for the District of Arizona, to Thomas Emerick, Assistant Special Agent in Charge, FDA 11/17/2010 000028-000029Department of Treasury Entry/Immediate Delivery Form 11/24/2010 000030-000031FDA's OASIS Screenshot for Entry # 112-9938358-2 n/a 000032Letter from Benjamin Rice, General Counsel, State of California, to Ruth Dixon, FDA 12/9/2010 000033Sodium Thiopental Statement, Key Messages 12/29/2010 000034-000035Email from Shelly Burgess to Nathan Koppel 1/4/2011 000036-000037Letter from Coleen Klasmeier, Bradford Berenson (Sidley Austin), and Dale Baich (Office of the Federal Public Defender for the District of Arizona), to Margaret Hamburg, Commissioner, FDA 1/4/2011 000038-000050Guidance for handling pending and future shipments of Sodium Thiopental 1/5/2011 000051-000057Notice of FDA Action 1/6/2011 000058-000059Notice of FDA Action 1/7/2011 000060-000061Letter from Patricia Shafer, Acting District Director, New Orleans District Office, to Benjamin Rice, Chief Counsel, California Department of Corrections & Rehabilitation 1/7/2011 000062-000063Letter from Alonza Cruse, District Director, Los Angeles District, to Carson McWilliams, Warden, Arizona State Prison Complex n/a 000064
MiscellaneousFDA Establishment Inspection Report for Sandoz - Endorsement Excerpt 7/8/2009 000065FDA Establishment Inspection Report for Sandoz - Summary Excerpt 7/29/2010 000066-000069Form FDA 483 - Inspectional Observations for Sandoz 7/29/2010 000070
2 of 2
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 4 of 74
FDA 000001
(b) (7)(E)
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 5 of 74
FDA 000002
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 6 of 74
FDA 000003
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 7 of 74
FDA 000004
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 8 of 74
FDA 000005
(b) (4)
(b) (4)
(b) (4)(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)(b) (4)(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (7)(C)
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 9 of 74
FDA 000006
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 10 of 74
FDA 000007
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 11 of 74
FDA 000008
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 12 of 74
FDA 000009
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 13 of 74
FDA 000010
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 14 of 74
FDA 000011
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 15 of 74
FDA 000012
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 16 of 74
FDA 000013
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 17 of 74
FDA 000014
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 18 of 74
FDA 000015
(b) (7)(E)
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 19 of 74
FDA 000016
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 20 of 74
FDA 000017
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 21 of 74
FDA 000018
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 22 of 74
FDA 000019
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 23 of 74
FDA 000020
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 24 of 74
FDA 000021
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 25 of 74
FDA 000022
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 26 of 74
FDA 000023
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 27 of 74
FDA 000024
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 28 of 74
FDA 000025
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 29 of 74
FDA 000026
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 30 of 74
(b) (7)(E)
FDA 000027
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 31 of 74
FDA 000028
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 32 of 74
FDA 000029
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 33 of 74
FDA 000030
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 34 of 74
FDA 000031
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 35 of 74
FDA 000032
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 36 of 74
FDA 000033
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 37 of 74
FDA 000034
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 38 of 74
FDA 000035
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 39 of 74
FDA 000036
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 40 of 74
FDA 000037
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 41 of 74
FDA 000038
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 42 of 74
FDA 000039
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 43 of 74
FDA 000040
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 44 of 74
FDA 000041
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 45 of 74
FDA 000042
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 46 of 74
FDA 000043
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 47 of 74
FDA 000044
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 48 of 74
FDA 000045
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 49 of 74
FDA 000046
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 50 of 74
FDA 000047
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 51 of 74
FDA 000048
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 52 of 74
FDA 000049
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 53 of 74
FDA 000050
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 54 of 74
FDA 000051
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 55 of 74
FDA 000052
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 56 of 74
FDA 000053
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 57 of 74
FDA 000054
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 58 of 74
FDA 000055
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 59 of 74
FDA 000056
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 60 of 74
FDA 000057
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 61 of 74
FDA 000058
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 62 of 74
FDA 000059
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 63 of 74
FDA 000060
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 64 of 74
FDA 000061
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 65 of 74
FDA 000062
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 66 of 74
FDA 000063
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 67 of 74
FDA 000064
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 68 of 74
FDA 000065
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 69 of 74
FDA 000066
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 70 of 74
FDA 000067
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 71 of 74
FDA 000068
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 72 of 74
FDA 000069
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 73 of 74
FDA 000070
Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 74 of 74